- Home
- CRIS vs REVB Comparison
CRIS vs REVB Comparison
Compare CRIS & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | REVB |
|---|---|---|
| Founded | 2000 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.9M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRIS | REVB |
|---|---|---|
| Price | $0.39 | $3.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | ★ 223.6K | 80.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | 72.68 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.33 | $0.44 |
| 52 Week High | $3,360.00 | $4.06 |
Technical Indicators
Market Signals| Indicator | CRIS | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 18.80 | 86.29 |
| Support Level | $0.34 | $0.97 |
| Resistance Level | $5.50 | N/A |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.77 | 0.30 |
| Stochastic Oscillator | 14.17 | 89.28 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.